---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-125062"
form_type: "8-K"
ticker: "MPLT"
cik: "0001770069"
company_name: "MapLight Therapeutics, Inc."
filed_at: "2026-03-26T23:59:59+00:00"
generated_at: "2026-05-15T08:51:57.821581+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# MapLight Q4 net loss $79.5M; cash $453M; Phase 2 readouts expected Q3 2026

## Summary
- Net loss of $79.5M in Q4 2025 vs $21.2M year ago; FY2025 loss $161.2M vs $77.6M.
- Cash, equivalents and investments $453.1M as of Dec 31, 2025, expected to fund operations through 2027.
- Phase 2 ZEPHYR trial for schizophrenia: target enrollment (n=300) expected April 2026; topline results Q3 2026.
- Phase 2 IRIS trial for autism spectrum disorder completed enrollment; topline results expected Q3 2026.
- FDA Fast Track granted for ML-007C-MA in Alzheimer's disease psychosis; VISTA trial topline H2 2027.

## SEC filing metadata
- accession: 0001193125-26-125062
- form_type: 8-K
- ticker: MPLT
- cik: 0001770069
- company_name: MapLight Therapeutics, Inc.
- filed_at: 2026-03-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770069/000119312526125062/0001193125-26-125062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770069/000119312526125062/mplt-20260326.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-125062
- JSON: https://secwatch.observer/filing/0001193125-26-125062.json
- Plain text: https://secwatch.observer/filing/0001193125-26-125062.txt

## Key facts
- Earnings Releases
  MapLight Therapeutics, Inc. reported the fourth quarter of 2025 results: net income $79.5 million.
  - Period: the fourth quarter of 2025
  - Net income: $79.5 million
  - Result: reported results
  source text: Net loss was $79.5 million for the fourth quarter of 2025, as compared to $21.2 million for the prior year period.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1770069/000119312526125062/0001193125-26-125062-index.htm
- Earnings Releases
  MapLight Therapeutics, Inc. reported the full year 2025 results: net income $161.2 million.
  - Period: the full year 2025
  - Net income: $161.2 million
  - Result: reported results
  source text: For the full year 2025, net loss was $161.2 million, as compared to $77.6 million for the full year 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1770069/000119312526125062/0001193125-26-125062-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.